Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 1-4 October 2018

October 5, 2018 – At its monthly meeting, the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) concluded a referral and confirmed its advice in the context of a safety signal evaluation. More information on all safety referrals currently under evaluation is provided in the table below. PRAC recommends restrictions on use of fluoroquinolone and quinolone antibiotics. Following a review of disabling and potentially … (leggi tutto)